All 8 advanced ovarian cancer, very sick patients were treated with Rubraca in one clinic and are now cancer free though maintaining with Rubraca at 200mg dose. It is a miracle.
Another good news that Rubraca is also a miracle drug to treat autoimmune diseases such as rheumatoid arthritis perhaps for its inducing expression of pd1 and ctla4. It will be a huge breakthrough. Notably, the induced pd1/ clta4 by Rubraca enhance the efficiency of anti pd1 & clta4 drug against cancer.
Good news about triple negative breast cancer coming soon
JP Morgan upgrades stock to "overweight"
@ Yahoo Reader, Excellent point. It would make real sense that 5FU is integrated into cancer genomic dna and makes damages to dna more efficiently than platin does. But damages to DNA alone would not stop cancer from repairing itself and cancer can survive as those cancers with Brca1 /2 mutations can keep going. When PARP inhibitors kick in, cancer with most dna damages won't be able to repair itself anymore and die away. In cell culture, Rubraca can enhance the fatality of cancer cell lines by 100-200% in same time frame when 5FU combined with Rubraca. On contrast, platinum slows down cancer cell growth by binding to dna and making dna replicate hard, but not directly damage DNA, which needs the secondary biological free radicals.
Given the expected positive results from ARIAL trail come thru...and some data at ASCO conf about other applications of the Rubraca, we can fly through 70s. Anecdotal evidence is huge....just waiting for trial confirmation with data.
looks great is Gilead making The Move
same pattern as yesterday, except going down more... this time
market up....wtfigo? 8% ystrdy and people take profit? r u nuts?
moving on up
Harry Boxer has posted his Charts of the Day video on CLVS at TheTechTrader site noting: Clovis Oncology Inc (CLVS) jumped 4.13, or 8%, to 54.63, on 2.2 million shares traded on Thursday. It has been up five days in a row, and had an exceptional rally back. It had a 3-wave corrective move in a larger rising channel. If that’s the case, especially if it gets up to the 58-60 range, not only does it take out lateral resistance, but it will complete taking out the declining topsline and 50-day moving average. It could take another run into the mid 60’s, and then the mid 70’s. Eventually, it will get much higher than that. Even a rally mid-range would get it to 65.
The chart looks very good. MACD and SMA50 divergence pointing to a breakout
Clinicians & patients all talk good of Rubraca, a very good sign.
One more good news that a small group of pancreatic cancer patients underwent 6months of FOLFIRINOX and did not control cancer progress, but, as last resort, all of them started taking Rubraca and all of their cancer lesion started shrinking in only two to three weeks. This was off label therapy. An oncologist thought FOLFIRINOX would make more sense to combine with PARP inhibitor than cis-platinum. Spread the words for sake of the deadly pancreatic cancer.
Rubraca is the most potent of PARP1 inhibitors as tested in cell free conditions by multiple lab. You can check it out online.
Clovis, Tesaro, AstraZeneca rating change at JPMorgan Clovis upgraded to Overweight from Neutral at JPMorgan. JPMorgan analyst Cory Kasimov upgraded Clovis Oncology (CLVS) to Overweight and raised his price target for the shares to $72 from $58. The stock closed yesterday up 2%, or $1.05, to $49.56. The shares are down 35% over the last two months for "no clear fundamental reason," Kasimov tells investors in a research note. The analyst is "increasingly comfortable" recommending Clovis ahead of its Phase 3 study evaluating Rubraca in maintenance ovarian cancer now that more PARP class data has emerged. He has not seen "convincing evidence" that there is a clear efficacy difference between Clovis' rucaparib, Tesaro's (TSRO) niraparib and AstraZeneca's (AZN) olaparib. Read more at: http://thefly.com/landingPageNews.php?id=2553683
Clovis upgraded to Overweight from Neutral at JPMorgan CLVS;TSRO;AZN - The Fly
Designed by market professionals, thefly.com has been reporting unbiased market intelligence to both professional and individual investors for more than 12 years. With information directly sourced from Wall Street traders, brokers, and institutional
Also Check out INCY report, their results are not so impressive, across board is 30% RR. Clearly PARP inhibitors are much more promising. Cheer up.
Studies seem to indicate that Tesaro's recently approved niraparib is more effective and has wider use than Clovis' rupacarib. You would think doctors will choose AZN's Lynparza or niraparib first.
it will run as soon as the market calm down a bit. indeed we caught a" bad day " for SUCH GREAT NEWS!
"The analyst believes the BRCA population is likely to be on par with other PARP inhibitors (within 3mo PFS benefit based on his doctor checks), but the all-comer result is the most meaningful for Rubraca because a broad label could more than double the addressable population." This is a very critical piece of information. The doctor checks means the information is very real-time and yes there could still be surprises, but the comfort level of the CEO and analyst, history of other such trials, and earlier results from Clovis, make me believe that Trial results are Great. CEO also talked about evidence they have (not from trial - but from doctors) about how great it was for other cancers. Overall very positive cycle.....Could propel this higher than 52 week high......